Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.76 |
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 3/20 | 0.47 |
| ▸ | VEGFA | P15692 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396187 | 0.89 | EGLN3 (0.76) | EGLN3EGLN1FTOFLT1VEGFA | |
| SCHEMBL3396850 | 0.87 | EGLN3 (1.00) | EGLN3EGLN1FTOFLT1VEGFA | |
| SCHEMBL3518354 | 0.82 | EGLN3 (0.51) | EGLN3EGLN1FTO | |
| SCHEMBL3522071 | 0.77 | EGLN3 (0.53) | EGLN3EGLN1FTO | |
| SCHEMBL3393384 | 0.77 | EGLN3 (0.70) | EGLN3EGLN1FTOFLT1VEGFA | |
| SCHEMBL3754317 | 0.75 | EGLN3 (0.55) | EGLN3EGLN1FTOFLT1VEGFA | |
| SCHEMBL3520318 | 0.75 | EGLN3 (0.55) | EGLN3EGLN1FTO | |
| SCHEMBL14389741 | 0.73 | KIF11 (0.48) | — | |
| SCHEMBL3521138 | 0.72 | EGLN3 (0.51) | EGLN3EGLN1FTOFLT1VEGFA | |
| SCHEMBL3396710 | 0.71 | EGLN3 (0.71) | EGLN3EGLN1FTOFLT1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | claimed |
| EP-2224926-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-08 | — | — | EP | claimed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | claimed |
| CN-101932324-A | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC | 2010-12-29 | — | — | CN | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2010-12-02 | — | — | US | disclosed |
| EP-2224926-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070644-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305154-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885FTO 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.